20 "Past Their Prime" Stocks to Dump From Your Portfolio

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Did you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ago? In 1987, IBM, Exxon, GE, Shell, AT&T, Merck, Du Pont, Philip Morris, Ford, and GM had the largest market caps on the S&P 500. ExxonMobil is the only company on that list to remain in the top 10 in 2023. Even 15 years ago, companies like Radio Shack, AOL, Yahoo, and Blockbuster were an important part of the S&P 500. Now, these companies no longer exist as public companies.

As the years go by, some companies lose their luster, and others rise to the top of the markets. We've already seen this in the last few decades, with tech companies surpassing industrial and energy companies that once dominated the S&P 500. It's hard to know what the next mega-trend will be that knocks Apple, Google, and Amazon off the top rankings of the S&P 500, but we know that companies don't stay on the S&P 500 forever.

We have identified 20 companies that are past their prime. They aren't at risk of a near-term delisting from the S&P 500, but they show negative earnings growth for the next several years. If you own any of these stocks, consider whether they still belong in your portfolio before they become the next Yahoo, Radio Shack, Blockbuster, AOL and are sold off for a fraction of their former value.

#1 - Brookfield Renewable Partners (NYSE:BEP)

Brookfield Renewable Partners L.P. owns a portfolio of renewable power generating facilities primarily in North America, Colombia, and Brazil. The company generates electricity through hydroelectric, wind, solar, distributed generation, and pumped storage, as well as renewable natural gas, carbon capture and storage, recycling, cogeneration biomass, nuclear services, and power transformation. Read More

Current Stock Price: $20.44
Dividend Yield: 6.75%
Consensus Rating: Moderate Buy
Ratings Breakdown: 6 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $30.60 (49.7% Upside)

#2 - Klaviyo (NYSE:KVYO)

Klaviyo, Inc, a technology company, provides a software-as-a-service platform in the United States, other Americas, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers Klaviyo, a cloud-native platform for data store, segmentation engine, campaigns and flows, and messaging infrastructure. Read More

Current Stock Price: $23.12
Consensus Rating: Moderate Buy
Ratings Breakdown: 13 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $36.88 (59.5% Upside)

#3 - Polestar Automotive Holding UK (NASDAQ:PSNY)

Polestar Automotive Holding UK PLC manufactures and sells premium electric vehicles. The company was founded in 2017 and is headquartered in Gothenburg, Sweden.

Current Stock Price: $1.39
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 2 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $3.83 (176.5% Upside)

#4 - Frontier Communications Parent (NASDAQ:FYBR)

Frontier Communications Parent, Inc, together with its subsidiaries, provides communication and technology services in the United States. It offers broadband, video, voice, and other value-added services. The company also provides data and Internet, including broadband networking services; data-based voice over internet protocol, unified communications, long-distance, and voice messaging services; video services under the Frontier TV brand; access services; hardware and network solutions; and packages of services. Read More

Current Stock Price: $22.88
P/E Ratio: 190.7
Consensus Rating: Moderate Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $27.43 (19.9% Upside)

#5 - Liberty Global (NASDAQ:LBTYA)

Liberty Global Ltd., together with its subsidiaries, provides broadband internet, video, fixed-line telephony, and mobile communications services to residential and business customers. It offers value-added broadband services, such as WiFi features, security, anti-virus, firewall, spam protection, smart home services, online storage solutions, and web spaces; and Connect Box that delivers in-home Wi-Fi service. Read More

Current Stock Price: $16.60
Consensus Rating: Hold
Ratings Breakdown: 3 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $26.36 (58.8% Upside)

#6 - MoonLake Immunotherapeutics (NASDAQ:MLTX)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Current Stock Price: $43.30
Consensus Rating: Moderate Buy
Ratings Breakdown: 9 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $74.46 (72.0% Upside)

#7 - EchoStar (NASDAQ:SATS)

EchoStar Corporation, together with its subsidiaries, provides networking technologies and services worldwide. The company operates in four segments: Pay-TV, Retail Wireless, 5G Network Deployment, Broadband and Satellite Services. The Pay-TV segment offers a direct broadcast and fixed satellite services; designs, develops, and distributes receiver system; and provides digital broadcast operations, including satellite uplinking/downlinking, transmission and, other services to third-party pay-TV providers; and multichannel, live-linear and on-demand streaming over-the-top internet-based domestic, international, Latino, and Freestream video programming services under the DISH and SLING brand names. Read More

Current Stock Price: $14.41
Consensus Rating: Moderate Buy
Ratings Breakdown: 2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $23.00 (59.6% Upside)

#8 - Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. Read More

Current Stock Price: $65.02
Consensus Rating: Buy
Ratings Breakdown: 10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $112.25 (72.6% Upside)

#9 - Lucid Group (NASDAQ:LCID)

Lucid Group, Inc a technology company, designs, engineers, manufactures, and sells electric vehicles (EV), EV powertrains, and battery systems. It also designs and develops proprietary software in-house for Lucid vehicles. The company sells vehicles directly to consumers through its retail sales network and direct online sales, including Lucid Financial Services. Read More

Current Stock Price: $2.53
Consensus Rating: Reduce
Ratings Breakdown: 0 Buy Ratings, 7 Hold Ratings, 3 Sell Ratings.
Consensus Price Target: $4.80 (89.7% Upside)

#10 - Liberty Live Group (NASDAQ:LLYVK)

Liberty Live Group operates in the media, communications, and entertainment industries primarily in North America and the United Kingdom. The company is headquartered in Englewood, Colorado.

Current Stock Price: $36.64
Consensus Rating: Buy
Ratings Breakdown: 1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: N/A

#11 - Brookfield Renewable (NYSE:BEPC)

Brookfield Renewable Corporation owns and operates a portfolio of renewable power and sustainable solution assets primarily in the United States, Europe, Colombia, and Brazil. It operates hydroelectric, wind, solar, and distributed energy and sustainable solutions with an installed capacity of approximately 19,161 megawatts. Read More

Current Stock Price: $22.01
Dividend Yield: 6.58%
Consensus Rating: Buy
Ratings Breakdown: 2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $34.00 (54.5% Upside)

#12 - Immunocore (NASDAQ:IMCR)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. Read More

Current Stock Price: $53.73
Consensus Rating: Moderate Buy
Ratings Breakdown: 10 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $80.55 (49.9% Upside)

#13 - Immunovant (NASDAQ:IMVT)

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. Read More

Current Stock Price: $28.24
Consensus Rating: Buy
Ratings Breakdown: 17 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $48.00 (70.0% Upside)

#14 - Alpine Immune Sciences (NASDAQ:ALPN)

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. Read More

Current Stock Price: $64.46
Consensus Rating: Hold
Ratings Breakdown: 3 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $50.33 (21.9% Downside)

#15 - Snowflake (NYSE:SNOW)

Snowflake Inc provides a cloud-based data platform for various organizations in the United States and internationally. Its platform offers Data Cloud, which enables customers to consolidate data into a single source of truth to drive meaningful business insights, build data-driven applications, and share data and data products, as well as applies artificial intelligence (AI) for solving business problems. Read More

Current Stock Price: $148.56
Consensus Rating: Moderate Buy
Ratings Breakdown: 22 Buy Ratings, 9 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $202.00 (36.0% Upside)

#16 - IDEAYA Biosciences (NASDAQ:IDYA)

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. Read More

Current Stock Price: $38.22
Consensus Rating: Buy
Ratings Breakdown: 13 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $44.55 (16.6% Upside)

#17 - Roblox (NYSE:RBLX)

Roblox Corporation develops and operates an online entertainment platform in the United States and internationally. It offers Roblox Studio, a free toolset that allows developers and creators to build, publish, and operate 3D experiences, and other content; Roblox Client, an application that allows users to explore 3D experience; and Roblox Cloud, which provides services and infrastructure that power the platform. Read More

Current Stock Price: $35.58
Consensus Rating: Moderate Buy
Ratings Breakdown: 16 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $46.25 (30.0% Upside)

#18 - Apogee Therapeutics (NASDAQ:APGE)

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Read More

Current Stock Price: $49.61
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $71.83 (44.8% Upside)

#19 - Cerevel Therapeutics (NASDAQ:CERE)

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. Read More

Current Stock Price: $42.05
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $41.40 (1.5% Downside)

#20 - Nuvalent (NASDAQ:NUVL)

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. Read More

Current Stock Price: $63.07
Consensus Rating: Moderate Buy
Ratings Breakdown: 9 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $90.78 (43.9% Upside)